Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ContiSol is a sterile, bicarbonate-buffered electrolyte solution developed by B. Braun for use in continuous renal replacement therapy (CRRT). It is primarily indicated as a replacement fluid in continuous veno-venous hemofiltration (CVVH) and continuous veno-venous hemodiafiltration (CVVHDF) for patients suffering from acute kidney injury or renal failure. The solution is designed to maintain or restore physiological electrolyte levels and acid-base balance, containing essential ions such as sodium, calcium, magnesium, and chloride, along with bicarbonate as a buffering agent to correct metabolic acidosis. ContiSol is available in various formulations, such as ContiSol 0 and ContiSol 4, which differ in their potassium concentrations to allow for individualized patient management based on serum electrolyte levels. The product is typically supplied in a two-compartment bag to ensure the stability of the bicarbonate and electrolytes until the point of administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ContiSol.